HF Logo HF Logo
Provider Home

Search

Resource Type
Clear All
Filter
Year
Sort By
Showing 157-168 of 550
Provider Alerts - Coronavirus (COVID-19) - General Update - 2022
COVID-19 Vaccine Counseling Program

In accordance with Medicaid COVID-19 vaccine regulations, Healthfirst will reimburse eligible providers for vaccine counseling rendered to unvaccinated Medicaid and HARP members/enrollees during dates of service on or after December 1, 2021. For providers located in New York City, this coverage essentially replaces the Vaccine Outreach and Counseling Program (VOCP) Healthfirst launched in collaboration with the New York City Department of Mental Hygiene in the fall of 2021, and which ended on December 31, 2021. If you provided services under the VOCP and have not yet billed for them, please bill in accordance with the requirements of the VOCP

Open document
COVID-19
  
Coronavirus (COVID-19) - Patient Care Resources - Practice Guidelines and Tips - 2022
The Flu and COVID-19 Frequently Asked Questions

Now that flu season is approaching, it's important to remember that the COVID-19 pandemic is still continuing around the world.

Open document
Seasonal Flu
  
Provider Alerts - Behavioral Health and Foster Care - Policy, Billing, or Coverage Update - 2021
Delayed: Applied Behavioral Analysis (ABA) Benefit Carve Out

The October 1, 2021 Applied Behavioral Analysis (ABA) benefit carve out into Managed Medicaid has officially been postponed by New York State Department of Health. Providers should continue to submit claims for ABA services to Medicaid Fee-For-Service directly until further notice.

Open document
Medicaid
  
Provider Alerts - Quality Program Resources - General Update - 2022
Celebrating Top Performers from the 2020 Healthfirst Quality Incentive Program (HQIP)

Thank you to all our providers for your hard work in the Healthfirst Quality Incentive Program. We would like to recognize the top performers from the 2020 HQIP for achieving the highest overall quality ratings among their peers.

Open document
HQIP
  
Provider Alerts - Coronavirus (COVID-19) - Policy, Billing, or Coverage Update - 2023
Billing Guidance for COVID-19 Vaccine Under Healthfirst’s Plans

Healthfirst continues to monitor COVID-19 vaccine updates from the state and federal government and from other healthcare agencies. This guidance provides billing information on COVID-19 vaccines. (Updated June 2023)

Open document
Billing
  
Provider Alerts - Claims & Billing - Policy, Billing, or Coverage Update - 2022
Transcranial Dopplers: Coding, Billing, and Medical Requirements

To ensure appropriate payments and maintain billing efficiencies, Healthfirst is committed to informing providers of specific requirements for the usage of any medical device. This alert provides guidance on Healthfirst coding, billing, and medical requirements for Transcranial Dopplers (TCD).

Open document
Billing
  
Provider Alerts - Claims & Billing - Coronavirus (COVID-19) - Policy, Billing, or Coverage Update - 2021
Coronavirus: Type (COVID-19) — Cost-Sharing Waiver

Please be advised that the New York State Department of Financial Services, the New York State Department of Health, and the federal government have directed Healthfirst to waive patient copayments, coinsurance, and deductibles for certain testing and treatment due to the coronavirus (COVID-19) emergency.

Open document
COVID-19
  
Provider Alerts - Claims & Billing - Policy, Billing, or Coverage Update - 2022
Billing for No-Cost Drugs and Biologicals

Healthfirst requires that providers record all substances administered to patients and that a charge be reported, even for no-cost drugs and biologicals. When this occurs, the provider or qualified healthcare professional should submit a token charge of $0 for the item.

Open document
Prior Authorization
  
Provider Alerts - Coronavirus (COVID-19) - Pharmacy Resources & Formularies - Provider Resources - 2023
COVID-19 Vaccine Additional Doses for Immunocompromised Individuals Pharmacy Billing Guidance

On August 13, 2021, the Advisory Committee on Immunization Practices (ACIP) met and recommended an additional dose for immunocompromised individuals who have received the Pfizer-BioNTech or Moderna COVID-19 vaccine.

Open document
Emergency Use Authorization
  
Provider Alerts - Coronavirus (COVID-19) - Pharmacy Resources & Formularies - Provider Resources - 2023
Pfizer-BioNtech, and Moderna, COVID-19 Booster Update Pharmacy Billing Guidance

The U.S. Food and Drug Administration has amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine to allow for a booster dose. Consult the individual EUA’s for current guidance.

Open document
Emergency Use Authorization
  
Provider Alerts - Coronavirus (COVID-19) - Pharmacy Resources & Formularies - Provider Resources - 2023
Zero-Cost COVID-19 Oral Antivirals Pharmacy Billing Guidance

Claims that providers submit for zero-cost COVID-19 oral antivirals must have either $0.01 in the Ingredient Cost Submitted field (NCPDP field 4Ø9-D9) or the combination of $0.00 in the Ingredient Cost Submitted field (NCPDP field 4Ø9-D9) and a value of “15” in the Basis of Cost Determination field (NCPDP field 423-DN).

Open document
Pharmacy Billing
  
Provider Alerts - Coronavirus (COVID-19) - Pharmacy Resources & Formularies - Provider Resources - 2023
New York Medicaid Guidance for At-Home COVID-19 Testing Coverage Update

Implementation of adjudication coding for at-home testing coverage for most New York Medicaid Managed Care Plan Sponsors should be completed by January 17, 2022. Providers receiving a reject message (e.g., reject code: 70 - NDC not covered, etc.) on COVID-19 at-home testing claims filled prior to January 17, 2022, should re-submit rejected claims after January 17, 2022.

Open document
Pharmacy Billing
  
You are now navigating away from the Healthfirst website.

Links to non-Healthfirst websites are provided for your convenience only. Healthfirst is not responsible or liable for the content, accuracy, or privacy practices of linked sites, or for products or services described on these sites.